EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
- Registration Number
- NCT04960202
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2246
- Confirmed SARS-CoV-2 infection within 5 days prior to randomization
- Initial onset of COVID-19 signs/symptoms within 5 days prior to the day of randomization and at least 1 of the specified COVID-19 signs/symptoms present on the day of randomization
- Fertile participants must agree to use a highly effective method of contraception
- Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19
- History of or need for hospitalization for the medical treatment of COVID-19
- Prior to current disease episode, any confirmed SARS-CoV-2 infection
- Known medical history of active liver disease
- Receiving dialysis or have known moderate to severe renal impairment
- Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment
- Suspected or confirmed concurrent active systemic infection other than COVID-19
- History of hypersensitivity or other contraindication to any of the components of the study intervention
- Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4
- Has received or is expected to receive convalescent COVID-19 plasma
- Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit
- Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit
- Known prior participation in this trial or other trial involving PF-07321332
- Oxygen saturation of <92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition
- Females who are pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Orally administered placebo PF-07321332/ritonavir PF-07321332 Orally administered PF-07321332+ritonavir PF-07321332/ritonavir Ritonavir Orally administered PF-07321332+ritonavir
- Primary Outcome Measures
Name Time Method Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population From Day 1 to Day 28 Percentage of participants with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method. Using KM method, survival probability for each time interval was calculated as the number of participants surviving divided by the number of participants at risk. Participants who had the event, dropped out, or moved out were not counted as "at risk" i.e., participants who were lost were considered "censored" and were not counted in the denominator.
- Secondary Outcome Measures
Name Time Method Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population From Day 1 (baseline) to Day 28 Sustained alleviation of all targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Number of Participants With AEs Leading to Discontinuation and Serious Adverse Events (SAEs) From start of study intervention (Day 1) up to end of safety follow-up (Day 34) An AE was any untoward medical occurrence in a participant, temporarily associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect; a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical events.
Time to Sustained Resolution of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) From start of study intervention (Day 1) up to end of safety follow-up (Day 34) An adverse event (AE) was any untoward medical occurrence in a participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect; a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical events. AEs included both SAEs and all non-SAEs. An AE was considered as TEAE if the event started on or after start date of study intervention.
Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT Population From Day 1 to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. The scale was reported as 0= no symptoms, 1=mild, 2=moderate and 3=severe. A participant with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of participants with severe Covid-19 signs and symptoms were reported.
Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT1 Population From Day 1 to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. The scale was reported as 0= no symptoms, 1=mild, 2=moderate and 3=severe. A participant with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of participants with severe Covid-19 signs and symptoms were reported.
Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT2 Population From Day 1 to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. The scale was reported as 0= no symptoms, 1=mild, 2=moderate and 3=severe. A participant with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of participants with severe Covid-19 signs and symptoms were reported.
Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population From Day 1 (baseline) to Day 28 Sustained alleviation of each targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when each symptom scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Plasma Concentration Versus Time Summary of PF-07321332 1 Hour post-dose on Day 1 and pre-dose on Day 5 Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat 1 (mITT1) Population From Day 1 to Day 28 Percentage of participants with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier method.
Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population From Day 1 (baseline) to Day 28 Sustained alleviation of all targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT Population From Day 1 (baseline) to Day 28 Sustained alleviation of each targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when each symptom scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Percentage of Participants Who Died Through Week 24- mITT Population From Day 1 up to Week 24 In this outcome measure, percentage of participants with death due to any cause was presented.
Percentage of Participants Who Died Through Week 24- mITT2 Population From Day 1 up to Week 24 In this outcome measure, percentage of participants with death due to any cause was presented.
Number of COVID-19 Related Medical Visits- mITT1 Population From Day 1 up to Day 34 Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalization (ICU and non-ICU stays). In this outcome measure, COVID-19-related medical visits of participants were reported.
Time to Sustained Resolution of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT2 Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT Population From Day 1 (baseline) to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).
Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT1 Population From Day 1 (baseline) to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).
Percentage of Participants With a Resting Peripheral Oxygen Saturation >=95% at Days 1 and 5- mITT1 Population Day 1, 5 In this outcome measure, the percentage of participants with a resting peripheral oxygen saturation \>=95% were reported.
Percentage of Participants With a Resting Peripheral Oxygen Saturation >=95% at Days 1 and 5- mITT2 Population Day 1, 5 In this outcome measure, the percentage of participants with a resting peripheral oxygen saturation \>=95% were reported.
Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT1 Population Baseline, Day 3, 5, 10 and 14 The viral load was measured in nasal or nasopharyngeal samples using RT-PCR.
Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT1 Population From Day 1 up to Day 34 Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- Modified Intent-to-Treat 2 (mITT2) Population From Day 1 (baseline) to Day 28 Sustained alleviation of all targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Time to Sustained Resolution of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Percentage of Participants Who Died Through Week 24- mITT1 Population From Day 1 up to Week 24 In this outcome measure, percentage of participants with death due to any cause was presented.
Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT2 Population Baseline, Day 3, 5, 10 and 14 The viral load was measured in nasal or nasopharyngeal samples using RT-PCR.
Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT Population From Day 1 up to Day 34 Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population From Day 1 (baseline) to Day 28 Sustained alleviation of each targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when each symptom scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period was considered date of first event. Time to sustained alleviation (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time was calculated as censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population From Day 1 (baseline) to Day 28 Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first.
Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT2 Population From Day 1 (baseline) to Day 28 Participants were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).
Percentage of Participants With a Resting Peripheral Oxygen Saturation >=95% at Days 1 and 5- mITT Population Day 1, 5 In this outcome measure, the percentage of participants with a resting peripheral oxygen saturation \>=95% were reported.
Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Day 3, 5, 10 and 14- mITT Population Baseline, Day 3, 5, 10 and 14 The viral load was measured in nasal or nasopharyngeal samples using reverse transcription polymerase chain reaction (RT-PCR).
Number of COVID-19 Related Medical Visits- mITT Population From Day 1 up to Day 34 Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalization (intensive care unit \[ICU\] and non-ICU stays). In this outcome measure, COVID-19-related medical visits of participants were reported.
Number of COVID-19 Related Medical Visits- mITT2 Population From Day 1 up to Day 34 Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalization (ICU and non-ICU stays). In this outcome measure, COVID-19-related medical visits of participants were reported.
Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT2 Population From Day 1 up to Day 34
Trial Locations
- Locations (199)
Cahaba Research Inc
🇺🇸Pelham, Alabama, United States
The Institute for Liver Health dba Arizona Clinical Trials
🇺🇸Tucson, Arizona, United States
Hope Clinical Research
🇺🇸Canoga Park, California, United States
Ark Clinical Research
🇺🇸Long Beach, California, United States
South Bay Clinical Research Institute
🇺🇸Redondo Beach, California, United States
Hope Clinical Research (COVID Satellite Site)
🇺🇸West Hills, California, United States
Future Innovative Treatments, LLC
🇺🇸Colorado Springs, Colorado, United States
MOORE Clinical Research, Inc.
🇺🇸Brandon, Florida, United States
Herco Medical and Research Center Inc
🇺🇸Coral Gables, Florida, United States
Advance Clinical Research Group
🇺🇸Cutler Bay, Florida, United States
Beautiful Minds Clinical Research Center
🇺🇸Cutler Bay, Florida, United States
Unlimited Medical Research Group, LLC
🇺🇸Hialeah Gardens, Florida, United States
Advanced Pulmonary Research Institute
🇺🇸Loxahatchee Groves, Florida, United States
Angels Clinical Research Institute
🇺🇸Miami, Florida, United States
NAPA Research LLC
🇺🇸Pompano Beach, Florida, United States
CDC Research Institute
🇺🇸Port Saint Lucie, Florida, United States
GCP, Global Clinical Professionals
🇺🇸Saint Petersburg, Florida, United States
Sunrise Research Institute
🇺🇸Sunrise, Florida, United States
USPA Advance Concept Medical Research Group LLC
🇺🇸South Miami, Florida, United States
New Orleans Sinus Center (COVID-19 Testing)
🇺🇸Marrero, Louisiana, United States
Tandem Clinical Research GI, LLC
🇺🇸Marrero, Louisiana, United States
Meridian Clinical Research, LLC
🇺🇸Endwell, New York, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
Accellacare
🇺🇸Wilmington, North Carolina, United States
Premier Medical Group
🇺🇸Clarksville, Tennessee, United States
PharmaTex Research, LLC
🇺🇸Amarillo, Texas, United States
St Hope Foundation
🇺🇸Bellaire, Texas, United States
Conroe Willis Medical Research
🇺🇸Conroe, Texas, United States
SMS Clinical Research, LLC
🇺🇸Mesquite, Texas, United States
SMS Clinical Research
🇺🇸Mesquite, Texas, United States
LinQ Research, LLC
🇺🇸Pearland, Texas, United States
Epic Medical Research
🇺🇸Red Oak, Texas, United States
Tranquility Research
🇺🇸Webster, Texas, United States
TPMG (Tidewater Physicians Multispecialty Group) Clinical Research
🇺🇸Newport News, Virginia, United States
Hospital Agamenon Magalhaes
🇧🇷Recife, Pernambuco, Brazil
CECIP JAÚ - Centro de Estudos Clínicos do Interior Paulista - LTDA
🇧🇷Jau, SAO Paulo, Brazil
Diagnostic-Consultative Center I Lom EOOD
🇧🇬Lom, Bulgaria
Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD
🇧🇬Lom, Bulgaria
Medical centre Leo Clinic EOOD
🇧🇬Lovech, Bulgaria
MHAT Heart and Brain EAD
🇧🇬Pleven, Bulgaria
MHAT "St. Panteleimon "- Plovdiv
🇧🇬Plovdiv, Bulgaria
DCC Sveti Georgi EOOD
🇧🇬Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD
🇧🇬Razgrad, Bulgaria
"Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -
🇧🇬Ruse, Bulgaria
UMHAT Medica Ruse OOD
🇧🇬Ruse, Bulgaria
Multiprofile Hospital for Active Treatment - Samokov EOOD
🇧🇬Samokov, Bulgaria
Medical Center-1-Sevlievo EOOD
🇧🇬Sevlievo, Bulgaria
Multiprofile hospital for active treatment - Sliven to Military Medical Academy
🇧🇬Sliven, Bulgaria
MHAT "Dr. Ivan Seliminski" AD, Sliven
🇧🇬Sliven, Bulgaria
MHAT "St. Sofia" EOOD
🇧🇬Sofia, Bulgaria
Diagnostic-Consultative Center XXII- Sofia ЕООD
🇧🇬Sofia, Bulgaria
Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD
🇧🇬Stara Zagora, Bulgaria
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD
🇧🇬Vratsa, Bulgaria
Medical center Leo Clinic EOOD
🇧🇬Varna, Bulgaria
Multiprofile Hospital for Active Treatment Targovishte AD
🇧🇬Targovishte, Bulgaria
Outpatient Clinic for Primary Outpatient Medical Care "Puls" - Dr. Mladen Buchvarov EOOD
🇧🇬Tsarevo, Bulgaria
Fundacion Cardiomet Cequin
🇨🇴Armenia, Quindio, Colombia
Zdraví-Fit, s.r.o.
🇨🇿Protivín, Czechia
Nemocnice Slany
🇨🇿Slany, Czechia
Trial Pharma Kft.
🇭🇺Gyula, Hungary
Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika
🇭🇺Debrecen, Hungary
AIIMS Raipur
🇮🇳Raipur, Chhattisgarh, India
Jupiter Hospital
🇮🇳Vadodara, Gujarat, India
BGS Global Institute of Medical Sciences and Hospital
🇮🇳Bangalore, Karnataka, India
Nil Ratan Sircar Medical College and Hospital
🇮🇳Kolkata, WEST Bengal, India
National Hokkaido Medical Center
🇯🇵Sapporo, Hokkaido, Japan
International University of Health and Welfare Narita Hospital
🇯🇵Narita, Chiba, Japan
Tokyo Medical University Hachioji Medical Center
🇯🇵Hachioji, Tokyo, Japan
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Incheon Medical Center
🇰🇷Incheon, Korea, Republic of
Chonnam National University Bitgoeul Hospital
🇰🇷Nam-gu, Korea, Republic of
SMG-SNU Boramae Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Umum Sarawak
🇲🇾Kuching, Sarawak, Malaysia
Hospital Miri
🇲🇾Miri, Sarawak, Malaysia
Clinical Research Institute Saltillo S.A. de C.V.
🇲🇽Saltillo, Coahuila, Mexico
Instituto Jalisciense de Metabolismo, S.C.
🇲🇽Guadalajara, Jalisco, Mexico
Asociacion Mexicana para la Investigacion Clinica A.C. (AMIC)
🇲🇽Pachuca de Soto, Hidalgo, Mexico
JM Research SC
🇲🇽Cuernavaca, Morelos, Mexico
Christus - Latam Hub Center of Excellence and Innovation Center S.C.
🇲🇽Monterrey, Nuevo LEON, Mexico
Eukarya Pharmasite S.C.
🇲🇽Monterrey, Nuevo LEON, Mexico
Oaxaca Site Management Organization
🇲🇽Oaxaca de Juarez, Oaxaca, Mexico
InfectoLab Consultorios de Especialidad en Infectologia
🇲🇽Baja California, Tijuana, Mexico
Kohler & Milstein Research S.A. de C.V.
🇲🇽Merida, Yucatan, Mexico
Centro de Investigacion Clinica Del Pacifico SA de CV
🇲🇽Acapulco, Mexico
Hospital Cardiologica Aguascalientes
🇲🇽Aguascalientes, Mexico
FAICIC S. de R.L. de C.V.
🇲🇽Veracruz, Mexico
Instituto de Investigaciones Clínicas para la Salud
🇲🇽Durango, Mexico
Sociedad de Metabolismo y Corazon S.C.
🇲🇽Veracruz, Mexico
Arké SMO S.A de C.V
🇲🇽Veracruz, Mexico
KLIMED Marek Klimkiewicz
🇵🇱Bialystok, Poland
Clinical Research Management Group Inc
🇵🇷Ponce, Puerto Rico
Advance Medical Research Center
🇵🇷San Juan, Puerto Rico
LLC Trekhgorka Medicine
🇷🇺Odintsovo, Moscow Region, Russian Federation
MERC Welkom
🇿🇦Welkom, FREE State, South Africa
Barnaul City Hospital Number 5
🇷🇺Barnaul, Russian Federation
KDC "Evromedservis", OJSC
🇷🇺Moscow, Russian Federation
Eba Centelles
🇪🇸Centelles, Barcelona [barcelona], Spain
Smolensk State Medical University
🇷🇺Smolensk, Russian Federation
East Rand Research Centre T/A Worthwhile Clinical Trials
🇿🇦Benoni, Gauteng, South Africa
Botho Ke Bontle Health Services
🇿🇦Pretoria, Gauteng, South Africa
MERC Middelburg
🇿🇦Middelburg, Mpumalanga, South Africa
Synapta Clinical Research Center
🇿🇦Durban, Kwazulu Natal, South Africa
Limpopo Clinical Research Initiative
🇿🇦Thabazimbi, Limpopo, South Africa
Complexo Hospitalario Universitario da Coruna
🇪🇸A Coruña, Spain
Faculty of Medicine - Khon Kaen University
🇹🇭Muang, Khon Kaen, Thailand
Ankara University Medical Faculty, Ibni-Sina Hospital
🇹🇷Ankara, Turkey
Hacettepe University Medical Faculty Hospital
🇹🇷Ankara, Turkey
Istanbul Medipol University Clinical Research Ethics Committee
🇹🇷Beykoz / Istanbul, Turkey
Gaziantep University Medical Faculty
🇹🇷Gaziantep, Turkey
Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi
🇹🇷Istanbul, Turkey
Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Acibadem Saglik Hizmetleri ve Tic.A.S, Acibadem Atakent Hastanesi
🇹🇷Istanbul, Turkey
Istanbul Universitesi Klinik Arastirmalar Mukemmeliyet Uygulama ve Arastirma Merkezi
🇹🇷Istanbul, Turkey
Basaksehir Cam ve Sakura Sehir Hastanesi
🇹🇷Istanbul, Turkey
Kocaeli University Medical Faculty
🇹🇷Kocaeli, Turkey
Sbü Dr. Suat Seren Göğüs Hastaliklari Ve Cerrahisi Eğitim Ve Araştirma Hastanesi
🇹🇷Konak/Izmir, Turkey
Mersin University Health Research and Application Hospital
🇹🇷Mersin, Turkey
Sakarya University Training and Research Hospital
🇹🇷Sakarya, Turkey
Karadeniz Teknik Universitesi Farabi Hastanesi
🇹🇷Trabzon, Turkey
Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council
🇺🇦Dnipro, Ukraine
Municipal Nonprofit Enterprise "Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of
🇺🇦Ivano-Frankivsk, Ukraine
Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council"
🇺🇦Ivano-Frankivsk, Ukraine
Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council
🇺🇦Kharkiv, Ukraine
Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases
🇺🇦Kharkiv, Ukraine
"Municipal Non-Profit Enterprise "Alexander Clinical Hospital of Kyiv" of the Kyiv City Council
🇺🇦Kyiv, Ukraine
Municipal non-commercial enterprise "Kyiv City Clinical Hospital #1" Of Executive Body Of the Kyiv
🇺🇦Kyiv, Ukraine
Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4"
🇺🇦Lviv, Ukraine
Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional
🇺🇦Poltava, Ukraine
Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council
🇺🇦Tarasove Village, Ukraine
Municipal Non-commercial Enterprise "Vinnytsia City Clinical Hospital №1"
🇺🇦Vinnytsia, Ukraine
Ascada Research
🇺🇸Fullerton, California, United States
American Institute of Research
🇺🇸Los Angeles, California, United States
Xera Med Research
🇺🇸Boca Raton, Florida, United States
Innovative Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
Qway Research
🇺🇸Hialeah, Florida, United States
Eastern Research Inc
🇺🇸Hialeah, Florida, United States
Inpatient Research Clinic
🇺🇸Hialeah, Florida, United States
Doral Medical Research LLC.
🇺🇸Hialeah, Florida, United States
Doral Medical Research,LLC
🇺🇸Hialeah, Florida, United States
Savin Medical Group, LLC
🇺🇸Miami Lakes, Florida, United States
Clinical Site Partners, Inc. dba CSP Orlando
🇺🇸Winter Park, Florida, United States
Research by Design, LLC
🇺🇸Chicago, Illinois, United States
Mercury Street Medical Group, PLLC
🇺🇸Butte, Montana, United States
South Texas Clinical Research
🇺🇸Corpus Christi, Texas, United States
SignatureCare Emergency Center
🇺🇸Houston, Texas, United States
Trio Clinical Trials, LLC
🇺🇸Houston, Texas, United States
C & R Research Services USA
🇺🇸Houston, Texas, United States
Next Level Urgent Care
🇺🇸Houston, Texas, United States
Jehangir Clinical Development Centre Pvt. Ltd
🇮🇳Pune, Maharashtra, India
Apex Hospitals Pvt Ltd
🇮🇳Jaipur, Rajasthan, India
Maharaja Agrasen Superspeciality Hospital
🇮🇳Jaipur, Rajasthan, India
Lisie Hospital
🇮🇳Kochi, Kerala, India
Chula Field Hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium)
🇹🇭Pathum Wan District,, Bangkok, Thailand
Bangkok Centre Hotel
🇹🇭Bangrak, Bangkok, Thailand
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),
🇹🇭Pathumwan, Bangkok, Thailand
Chronos Pesquisa Clinica
🇧🇷Brasilia, Distrito Federal, Brazil
Thai Red Cross Emerging Infectious Diseases (EDI) Clinic
🇹🇭Pathumwan,, Bangkok, Thailand
Jawahar Lal Nehru Medical College
🇮🇳Ajmer, Rajasthan, India
Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,
🇹🇭Hat Yai, Songkhla, Thailand
Instituto de Investigaciones Clinicas Zarate
🇦🇷Zarate, Buenos Aires, Argentina
Aakash Healthcare Private Limited
🇮🇳New Delhi, India
Sardar Patel Medical College
🇮🇳Pavan PURI Bikaner, Rajasthan, India
Multiprofile Hospital For Active Treatment Shumen AD
🇧🇬Shumen, Bulgaria
Hospital De Clínicas Presidente Dr.Nicolas Avellaneda
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Agria-Study Kft.
🇭🇺Eger, Hungary
Medifarma-98 Kft.
🇭🇺Nyiregyhaza, Hungary
Individual Practice for Primary Medical Care - IPPMC - Dr. P. Panayotov EOOD
🇧🇬Burgas, Bulgaria
"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd
🇧🇬Haskovo, Bulgaria
MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD
🇧🇬Kozloduy, Bulgaria
National Center for Global Health and Medicine
🇯🇵Shinjuku City, Tokyo, Japan
Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska
🇵🇱Wroclaw, Poland
Communal Enterprise "Hospital #1" of Zhytomyr City Council
🇺🇦Zhytomyr, Ukraine
Lifepoint Research LLP
🇮🇳Pune, Maharashtra, India
Rinku General Medical Center
🇯🇵Izumisano, Osaka, Japan
Municipal NonProfit Enterprise of the Lviv Regional Council Lviv Regional Information and Analitical
🇺🇦Lviv, Ukraine
Akdeniz Universitesi Hastanesi
🇹🇷Antalya, Turkey
Kyiv Railway Clinical Hospital No.2 of Branch "Health Center of the Public Joint Stock Company
🇺🇦Kyiv, Ukraine
Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company
🇺🇦Kyiv, Ukraine
Atella Clinical Research LLC.
🇺🇸La Palma, California, United States
Premium Medical Research Corp
🇺🇸Miami, Florida, United States
C'A Research
🇺🇸Miami, Florida, United States
Entrust Clinical Research
🇺🇸Miami, Florida, United States
LCC Medical Research Institute, LLC
🇺🇸Miami, Florida, United States
Global Health Clinical Trials Corp
🇺🇸Miami, Florida, United States
South Florida Research Center, Inc.
🇺🇸Miami, Florida, United States
Suncoast Research Group, LLC
🇺🇸Miami, Florida, United States
I.V.A.M. Clinical & Investigational Center, LLC
🇺🇸Miami, Florida, United States
ProLive Medical Research, Corp.
🇺🇸Miami, Florida, United States
Reed Medical Research
🇺🇸Miami, Florida, United States
Kendall South Medical Center
🇺🇸Miami, Florida, United States
Clinical Site Partners, Inc d/b/a CSP Miami
🇺🇸Miami, Florida, United States
Coral Research Clinic Corp
🇺🇸Miami, Florida, United States
Santos Research Center, CORP
🇺🇸Tampa, Florida, United States
Excel Clinical Research
🇺🇸Las Vegas, Nevada, United States
Sun Research Institute
🇺🇸San Antonio, Texas, United States
BFHC Research
🇺🇸San Antonio, Texas, United States
Omega Research Orlando, LLC
🇺🇸Orlando, Florida, United States
ARC Clinical Research at William Cannon
🇺🇸Austin, Texas, United States
EME RED Hospitalaria
🇲🇽Mérida, Yucatán, Mexico